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Abstract
AIM: To explore gastroenterologist perceptions towards 
and experience with faecal microbiota transplantation 
(FMT).
METHODS: A questionnaire survey consisting of 17 
questions was created to assess gastroenterologists’ 
attitude towards and experience with FMT. This was 
anonymously distributed in hard copy format amongst 
attendees at gastroenterology meetings in Australia 
between October 2013 and April 2014. Basic descriptive 
statistical analyses were performed.
RESULTS: Fifty-two clinicians participated. Twenty 
one percent had previously referred patients for FMT, 
8% more than once. Ninety percent would refer 
patients with Clostridium difficile  infection (CDI) for 
FMT if easily available, 37% for ulcerative colitis, 
13% for Crohn’s disease and 6% for irritable bowel 
syndrome. Six percent would not refer any indication, 
including recurrent CDI. Eighty-six percent would enroll 
patients in FMT clinical trials. Thirty-seven percent 
considered the optimal mode of FMT administration 
transcolonoscopic, 17% nasoduodenal, 13% enema 
and 8% oral capsule. The greatest concerns regarding 
FMT were: 42% lack of evidence, 12% infection risk, 
10% non infectious adverse effects/lack of safety 
data, 10% aesthetic, 10% lack of efficacy, 4% disease 
exacerbation, and 2% inappropriate use; 6% had no 
concerns. Seventy seven percent believed there is 
a lack of accessibility while 52% had an interest in 
learning how to provide FMT. Only 6% offered FMT at 
their institution.
CONCLUSION: Despite general enthusiasm, most 
gastroenterologists have limited experience with, or 
access to, FMT. The greatest concerns were lack of 
supportive evidence and safety issues. However a 
significant proportion would refer indications other than 
CDI for FMT despite insufficient evidence. These data 
provide guidance on where education and training are 
required. 
Key words: Perceptions; Gastroenterologist; Clostridium 
difficile ; Inflammatory bowel disease; Faecal microbiota 
transplantation
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Core tip: This is the first study assessing the expe-
riences, attitudes and practice of gastroenterologists 
towards faecal microbiota transplantation (FMT) across 
a range of indications other than just Clostridium 
difficile  infection. Despite general enthusiasm, most 
gastroenterologists have limited experience with, 
or access to, FMT. Views differ widely regarding the 
potential therapeutic role of FMT in various gastroin-
testinal diseases. Major concerns include lack of 
evidence and safety data, infection risk, aesthetic factors 
and possible lack of efficacy. There is limited familiarity 
with the current evidence base and appropriate 
indications for FMT highlighting the need for education 
on where FMT fits in to current clinical practice.
Paramsothy S, Walsh AJ, Borody T, Samuel D, van den 
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INTRODUCTION
The last few years has seen a surge in interest in 
faecal microbiota transplantation (FMT)[1]. While not 
a new treatment, until recently it was regarded as an 
“alternative” therapy with little scientific basis, outside 
the realm of mainstream medical practice and offered 
by only a handful of centres worldwide. The dramatic 
change is largely attributable to the remarkable 
efficacy of FMT in recurrent Clostridium difficile 
infection (rCDI) at a time of a global CDI epidemic[2,3]. 
The cure rate of approximately 90% for FMT in rCDI[4-6] 
is much superior to the 20%-30% success rates 
associated with prolonged anti-microbial therapy.
The rapid advancements in gastrointestinal 
microbiota research including the work of large national 
and multinational collaborative projects such as the 
Human Microbiome Project[7,8] have further fueled 
interest in the role of the gastrointestinal microbiota 
in health and disease, and the therapeutic potential 
of FMT. Such research has linked gastrointestinal 
dysbiosis to enteric[9] conditions as varied as 
inflammatory bowel disease (IBD)[10,11], irritable bowel 
syndrome (IBS), and colorectal cancer[12], and to 
systemic conditions including obesity and metabolic 
syndrome[13,14], cardiovascular disease[15], and liver 
disease[16]. Clinical trials are currently underway in 
several of these conditions.
The role of the gastrointestinal microbiota in health 
and disease and the “promise” of FMT has captured 
the attention of patients, the general community and 
mainstream media. Patients are attracted to FMT as 
they perceive it as a “natural” and “holistic” therapy 
which seems safer than long term medications and 
their associated side effects[17]. This is despite a 
lack of long term safety data and initial reports of 
potential far reaching complications[18]. Studies have 
demonstrated that the aesthetics of using faecal 
material is not as significant a deterrent for patients as 
previously expected[19,20]. There appears to be patient 
enthusiasm to make this therapy available for a range 
of conditions, despite the paucity of evidence outside 
the setting of CDI. This is reflected in the number of 
patient FMT self-help and do it yourself websites and 
forums. 
The view of gastroenterologists towards FMT is 
less clear. While there is increasing research in the 
field of FMT, this appears to be tempered by concerns 
about lack of efficacy and safety data, and ongoing 
skepticism regarding the mechanism of action of FMT 
therapy[20]. There are only a few reports assessing the 
sentiments of gastroenterologists and other physicians 
with regards to FMT in CDI[21,22]. To our knowledge, 
the perceptions of gastroenterologists towards FMT 
for indications other than CDI has not been assessed. 
This survey of Australian gastroenterologists aimed 
to determine the wider gastroenterology community 
attitudes towards, and experience with, FMT. 
MATERIALS AND METHODS
A questionnaire survey was created to assess 
gastroenterologists’ attitude towards and experience 
with FMT (Table 1). It consisted of 17 questions. This 
was anonymously distributed in hard copy format 
amongst attendees at gastroenterology meetings in 
Australia between October 2013 and April 2014. Basic 
descriptive statistical analyses were performed using 
SPSS Statistics Version 22.0.
RESULTS
Respondents
52 clinicians participated in the survey. Subspecialty 
breakdown of respondents is shown in Figure 1. 
The general physicians included in the data set are 
those with dual training or a specialty interest in 
gastroenterology. With regards to nature of practice, 14 
(27%) were public hospital staff specialists, 13 (25%) 
visiting medical officers, 11 (21%) solely in private 
practice, 10 (19%) trainee gastroenterologists in the 
public hospital system, 3 (6%) public hospital staff 
specialists with associated private practice, and 1 (2%) 
a predominantly research-based gastroenterologist. 
Experience with FMT
Twenty-seven respondents (52%) had never been 
consulted by a patient who had received FMT before. 
Eleven (21%) reported having referred a patient for 
FMT: 7 respondents (13%) had referred a patient 
for FMT once, 1 respondent (2%) three times, 1 
respondent (2%) four times, 1 respondent (2%) 
six times and 1 respondent (2%) over one hundred 
times. Three respondents (6%) were offering FMT as a 
therapeutic option at their practice or institution. 
Current stance on FMT indications
The current stance of respondents towards various 
FMT indications is shown in Figure 2. Forty-seven 
respondents (90%) would refer patients with CDI 
for FMT if it were easily available. Regarding other 
indications, 19 (37%) would refer patients with 
ulcerative colitis, 7 (13%) for Crohn’s disease and 3 
(6%) for IBS. Three (6%) would not consider referring 
for FMT for any indication. No respondent reported 
that they would advise against FMT if approached by 
a patient interested in undergoing such treatment; 3 
(6%) reported they were ambivalent, 15 (29%) stated 
they would acknowledge the patient’s interest and 
refer for FMT, 26 (50%) would only refer for FMT for 
the indication of rCDI while 21 (40%) would suggest 
patients only participate in clinical trials of FMT. Forty 
five respondents (86%) would be willing to enroll their 
patients in clinical trials assessing FMT, three (6%) 
were unsure and 1 (2%) was not willing [3 (6%) non 
respondents]. Twenty-six (50%) would consider FMT 
as a last resort therapy for a medical condition where 
FMT was speculated to have benefit if their patient had 
refractory disease and was facing surgery while 12 
(23%) said they would only do so in the context of a 
clinical trial.
Perceived efficacy of FMT
Regarding the statement “I don’t believe in FMT 
and I don’t think it is an effective therapy”: 1 (2%) 






















































Figure 2  Perceived faecal microbiota transplant indications.
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Table 1  Gastroenterologist “faecal microbiota transplantation” perceptions survey
Gastroenterologist “faecal microbiota transplantation” (fmt) perceptions survey
1: How would you best describe yourself? (may select more than one option)
a: General Gastroenterologist
b: Hepatology subspecialist
c: Inflammatory Bowel Disease subspecialist
d: Advanced/Therapeutic endoscopy subspecialist
e: Gastroenterology trainee
f: Other; please describe in space below
2: What is the nature of your practice/work? (may select more than one option)
a: Staff Specialist
b: Public Hospital Visiting Medical Officer
c: Private Practice
d: > 40% Medical Research
e: Other; please describe in space below





e: Irritable bowel syndrome
f: Other; please describe in space below
4: Have you ever referred a patient for FMT before?
a: Yes – please elaborate in space below (indication, number of referrals, outcome)
b: No




d: Irritable bowel syndrome
e: Other; please list in space below
f: I would not consider referring for FMT for any indication
6: If a patient saw you and expressed interest in undergoing FMT would you (you may select more than one option)
a: Advise against it
b: Remain ambivalent
c: Acknowledge their interest and refer them for FMT
d: Only refer them for FMT for the indication of recurrent Clostridium difficile
e: Suggest they only participate in clinical trials involving FMT
f: Other; please describe in space below
7: Please select your response in answer to each of the following potential concerns with FMT
a: I don’t believe in FMT and I don’t think it is an effective therapy
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
b: While FMT may work at present there is inadequate evidence for efficacy
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
c: There is a significant infection risk from donor stool despite screening
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
d: I have other safety concerns regarding non-infectious adverse reactions with FMT
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
e: There is a risk of disease exacerbation with FMT
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
f: I don’t think my patients would contemplate or consent to FMT 
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
g: “Yuck” factor (Aesthetics)
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
h: Lack of availability/accessibility to FMT
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
i: Other; please describe in space below
8: What is your greatest concern, if any, regarding FMT? Please select only one
a: Lack of efficacy
b: Lack of evidence
c: Infection risk from donor stool despite screening
d: Non infectious adverse reaction and lack of safety data
e: Possible disease exacerbation
f: “Yuck” factor of donor stool
g: None; I have no concerns regarding FMT
h: Other; please list in space below
9: How do you feel the potential risks of FMT compare with blood transfusion or other biologic product administration?
a: More risk with blood transfusion than FMT
b: More risk with FMT than blood transfusion
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strongly agreed, 7 (14%) somewhat agreed, 20 (38%) 
somewhat disagreed and 22 (42%) strongly disagreed 
[2 (4%) non respondents]. Regarding the statement 
“While FMT may work at present there is inadequate 
evidence for efficacy”: 6 (12%) strongly agreed, 
25 (48%) somewhat agreed, 13 (25%) somewhat 
disagreed and 6 (12%) strongly disagreed [2 (4%) 
non respondents].
Perceived safety of FMT
Thirteen respondents (25%) somewhat agreed that 
there was a significant infection risk from donor 
stool despite screening, while 27 (52%) somewhat 
disagreed and 10 (19%) strongly disagreed [2 
(4%) non respondents]. Regarding safety concerns 
pertaining to non infectious adverse reactions with 
FMT, 1 (2%) strongly agreed, 18 (34%) somewhat 
agreed, 26 (50%) somewhat disagreed and 6 (12%) 
strongly disagreed [1 (2%) non respondents]. 21 
respondents (40%) somewhat agreed there was a risk 
of disease exacerbation with FMT, 26 (50%) somewhat 
disagreed and 3 (6%) strongly disagreed [2 (4%) non 
respondents]. Twenty four respondents (46%) felt 
the potential risks of FMT were less than for a blood 
transfusion or other biologic product administration, 
24 (46%) were unsure and 2 (4%) felt FMT was more 
10911 October 14, 2015|Volume 21|Issue 38|WJG|www.wjgnet.com
c: Not sure
d: Other; please describe in space below




d: Other; please list in space below
e: I don’t have an opinion
11: If your patient had exhausted all other medical options and was facing surgery for refractory disease in which FMT has been suggested as a 
potential therapeutic option, would you consider FMT as a last resort therapy?
a: Yes
b: Yes but only for Clostridium difficile
c: Yes but only in a clinical trial
d: Not sure
e: No
f: Other; please describe in space below




d: Other; please describe in space below




d: Other; please describe in space below
14: In the next 3 yr, do you foresee a situation where you would consider referring a patient for FMT outside a clinical trial if a trusted service was 
available? Please select your answer for each of the following indications 
a. No, I would not consider referring for FMT for any indication
b: Recurrent Clostridium difficile infection
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
c: Ulcerative Colitis
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
d: Crohn’s disease
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
e: Irritable bowel syndrome or other functional gut disorder
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
15: With regards to FMT, please select your response to the following statements
a: I already offer FMT as a therapeutic option in my practice
b: I have an interest in learning how to process and administer FMT so that I or my institution can arrange such therapy for our patients independently
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
c: I believe a few select centres that satisfy appropriate regulatory requirements should be available in my city to offer FMT
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
d: I don’t believe the therapy should be available for routine clinical use 
Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree
16: After reviewing the attached FOCUS study letter of invitation, protocol summary and selection criteria
a: Are you likely to refer patients who meet selection criteria to this study?
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
b: Do you have any actual patients in mind that you would consider referring to this study?
Highly Likely Somewhat Likely Somewhat Unlikely Highly unlikely
17: Any other comments regarding FMT that you wish to make?
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risky than a blood transfusion or other biologic product 
administration [2 (4%) non respondents].
Perceived patient acceptance of FMT
One respondent (2%) strongly believed that their 
patients would not contemplate or consent to FMT, 
13 (25%) somewhat agreed, 28 (54%) somewhat 
disagreed and 9 (17%) strongly disagreed [1 (2%) 
non respondent]. Nine respondents (17%) strongly 
believed their patients would be put off by the 
aesthetics of FMT, 24 (46%) somewhat agreed, 12 
(23%) somewhat disagreed while 6 (12%) strongly 
disagreed [1 (2%) non respondent]. 
Greatest concerns regarding FMT
The greatest concerns regarding FMT are shown in 
Figure 3. Lack of evidence was the most commonly 
cited concern (42%) with safety/adverse events 
(infectious and non infectious), lack of efficacy and 
aesthetic factors also reported frequently. 
Availability and accessibility of FMT
Seventy-seven percent of respondents agreed that 
there is a lack of availability or accessibility to FMT. 
Fifty two percent had an interest in learning how to 
process and administer FMT so their institution could 
offer the therapy. Seventy-nine percent agreed (35% 
strongly agreed, 44% somewhat agreed) with the 
statement that a few centres that satisfy appropriate 
regulatory requirements should be available in any 
area or region to offer FMT. Regarding the statement 
that FMT should not be available for routine clinical 
use, 3 (6%) strongly agreed, 14 (27%) somewhat 
agreed, 22 (42%) somewhat disagreed and 8 (15%) 
strongly disagreed [5 (10%) non respondents].
Route of administration and future of FMT
Figure 4 shows the perceived optimal modality of FMT 
administration with the transcolonoscopic route most 
popular (37%) followed by nasoduodenal (17%), 
while a significant proportion had no opinion. When 
asked if they thought FMT held promise as a future 
therapy for certain gastrointestinal diseases, 77% 
said yes, 15% were unsure and 4% said no. (4% non 
respondent). When asked whether in the next 3 years 
they could foresee referring for FMT outside a clinical 
trial if a trusted service was available, none stated 
no for all indications, 60% said highly likely and 29% 
somewhat likely for rCDI, 13% said highly likely and 
50% somewhat likely for UC, 4% said highly likely and 
44% somewhat likely for Crohn’s disease, 31% said 
somewhat likely, 33% somewhat unlikely and 31% 
said highly unlikely for IBS.
DISCUSSION
To our knowledge this is the first report assessing the 
perception and practice of gastroenterologists towards 
FMT across a range of indications other than rCDI. 
This study suggests that views vary widely amongst 
gastroenterologists regarding the role of FMT. Despite 
general enthusiasm, experience with FMT remains 
limited and lack of accessibility appears to be a 
contributing factor.
The most commonly reported concern by 
gastroenterologists regarding FMT was the lack of 
evidence about efficacy. Almost 60% felt that while 
FMT may be effective, at present there is inadequate 
supportive evidence and this was the major concern 
cited by almost half of respondents. However at the 
same time, despite a limited evidence base many 
gastroenterologists advocated FMT for indications 
other than rCDI. Over a third reported they would 
refer their UC patients for FMT if easily available, 10% 
would refer Crohn’s disease, and 6% for IBS. Almost 
a third were happy to refer patients with non CDI 
indications for FMT outside a clinical trial setting. At the 
other extreme, around 15% did not believe FMT was 
an effective therapy and a small proportion would not 













































































































































Figure 4  Optimal modality of administration.
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refer any patient for FMT, even in the setting of CDI, 
despite the growing body of evidence demonstrating 
efficacy and short term safety of this therapy in a 
condition with significant morbidity and mortality.
The majority of surveyed gastroenterologists did not 
express reservations regarding the safety of FMT from 
infection transmission, other non infectious adverse 
events or disease exacerbation, despite relatively 
limited short term data and negligible long term data. 
Almost three quarters of gastroenterologists 
surveyed believed their patients would contemplate or 
consent to FMT, though almost two thirds believed they 
would be concerned by the aesthetic factor. Published 
studies on patient perception towards FMT have found 
a majority would consider such therapy and that 
the aesthetic factor is not a major issue, suggesting 
the perception of gastroenterologists are only partly 
consistent with those of their patients[17,19]. However 
there appears to be improvement in gastroenterologist 
awareness of patient attitudes towards FMT compared 
to the earliest report assessing gastroenterologist 
perceptions of FMT in which 71% cited lack of patient 
acceptance and tolerability as the main barrier to FMT 
for CDI[21]. 
Half the respondents felt a lower gastrointestinal 
route was the optimal mode of FMT administration, 
with only a quarter advocating an upper gastro-
intestinal route and the remainder not having an 
opinion. These findings may be influenced to some 
degree by the ease of endoscopic access and admini-
stration available to gastroenterologists. A small 
number volunteered that oral capsule would be the 
optimal method despite this not being listed as a pre-
specified choice on the questionnaire and minimal 
publications at the time of survey distribution reporting 
its use; the evidence for such a mode of delivery in 
rCDI is only just appearing in clinical trials. 
Over three quarters of respondent gastroentero-
logists believe FMT holds promise as a potential 
therapy for certain gastrointestinal diseases, and 
would be willing to enroll their patients in FMT clinical 
trials. In the next 3 years, the majority expected they 
would be referring patients for FMT outside a clinical 
trial setting for both rCDI and UC if a trusted service 
was available, almost 50% for Crohn’s disease and one 
third for IBS. This represents a significant shift in the 
last few years from when less than half of respondent 
gastroenterologists would consider FMT in the setting 
of CDI[21], despite arguably more convincing evidence 
at that stage for FMT in CDI than currently exists for 
FMT in non CDI settings.
A limitation of this study is the relatively small total 
respondent number. Furthermore, it was not possible 
to determine the response rate as the method of 
survey distribution involved circulating hard copies of 
the questionnaire at gastroenterology meetings rather 
than formal mailbox or email distribution. Finally, 
all respondents were Australian gastroenterologists, 
the majority from Sydney, potentially limiting the 
generalisability of the responses. 
This study is the first report of gastroenterologist 
practice and perceptions regarding the use of FMT 
to include indications beyond rCDI. It highlights 
that while there is a large degree of interest in FMT 
amongst the profession, experience remains limited 
and opinions conflicting regarding its therapeutic 
potential and safety, sometimes inconsistent with the 
current medical evidence base. It indicates areas of 




Faecal microbiota transplantation (FMT) has attracted substantial interest over 
recent years from researchers, clinicians, patients and mainstream media due 
to its extraordinary efficacy in the treatment of recurrent Clostridium difficile 
infection (rCDI), a condition with significant morbidity and mortality. As a result, 
there is growing interest in exploring the potential for FMT in the treatment 
of other disease states where pathogenesis is presumed to be secondary to 
dysbiosis. However concerns have been raised about the lack of efficacy and 
safety data along with limited accessibility and experience outside specialized 
centres.
Research frontiers
While interest in FMT is growing, controversy exists regarding potential 
indications, efficacy and safety for FMT. While patient perceptions of FMT have 
been reported and suggest widespread interest and enthusiasm, the overall 
opinions and experience of gastroenterologists related to FMT are not clear and 
have not been studied for conditions other than just CDI. The research hotspot 
this study addresses is to explore gastroenterologist attitudes towards, and 
experience with, FMT in general.
Innovations and breakthroughs
In recent years, uncontrolled and controlled studies have demonstrated that 
FMT is highly effective in the treatment of CDI. However data is still lacking 
regarding long term safety and non infectious adverse events. Controlled 
efficacy data for other potential indications are required though several clinical 
trials are currently underway.
Applications
This study suggests that while there is general interest in FMT, experience 
and accessibility are major limiting factors for most gastroenterologists that 
need to be addressed. Knowledge of current evidence based indications was 
suboptimal suggesting the need for further education and training. The greatest 
concerns were lack of supportive evidence and safety issues, highlighting areas 
for future research.
Terminology
FMT involves the transfer of faecal material (and associated microbiota) from a 
healthy donor to a recipient for the purpose of treating an underlying disease. 
The mechanism of action is generally believed to be via correction of underlying 
disease dysbiosis. Dysbiosis is a disturbance in the natural balance of the 
microbial ecology of a part of the body.
Peer-review
An informative paper, suitable for educational purposes and with potential to be 
of general interest because the topic is controversial and current.
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